42 results match your criteria: "Department of Clinical Geratology[Affiliation]"

Article Synopsis
  • Many older patients with COPD are not having timely discussions about end-of-life care (EOLC) with healthcare professionals, despite a strong preference for such conversations.
  • A study at the University Hospital Center Osijek in Croatia found that 77% of COPD patients aged 65 and older had not discussed EOLC with their healthcare providers, while 64% wanted to talk about it, especially during hospital stays.
  • Healthcare professionals also recognize the importance of these discussions (77%) but often feel uncomfortable initiating them, leading to a gap in care that could negatively impact the quality of life for older patients with advanced COPD.
View Article and Find Full Text PDF

We describe a case of a 67-year-old man with known chronic obstructive pulmonary disease, type 2 diabetes mellitus, hypertension, osteoarthritis, previous history of excess alcohol intake, and oesophagectomy 3 years earlier for T3N0 adenocarcinoma, referred by his general practitioner with confusion, weight loss and several recent falls. CT of the chest, abdomen and pelvis revealed a right middle-lobe pulmonary embolism, while CT of the head revealed a communicating hydrocephalus. Lumbar puncture was performed, and empirical treatment for tuberculous and fungal meningitis was commenced.

View Article and Find Full Text PDF

Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium.

Am J Geriatr Psychiatry

April 2015

Trinity College Institute of Neuroscience, School of Biochemistry and Immunology, Trinity College Dublin, Republic of Ireland. Electronic address:

Background: Delirium is a profound neuropsychiatric disturbance precipitated by acute illness. Although dementia is the major risk factor this has typically been considered a binary quantity (i.e.

View Article and Find Full Text PDF

Treating chronic non-cancer pain in older people--more questions than answers?

Maturitas

September 2014

Pain Research and Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. Electronic address:

There is little evidence specifically relating to drug treatments for pain in older people, but much can be extrapolated from what we already know. The evidence about drug treatments for chronic non-cancer pain is changing, driven by major improvements in understanding of clinical trial analysis and by the adoption of patient-centered outcomes of proven economic benefit. There is clear evidence of lack of useful effect, or insufficient evidence of effect for a number of commonly used drugs, including paracetamol, topical rubefacients, low concentration topical capsaicin, and for strong opioids in chronic non-cancer pain.

View Article and Find Full Text PDF

Pain treatment--bad news and good.

J Am Geriatr Soc

July 2014

Department of Clinical Geratology, John Radcliffe Hospital, Oxford University Hospitals National Health Service Trust, Oxford, UK; Pain Research and Nuffield Division of Anaesthetics, Churchill Hospital, University of Oxford, Oxford, UK.

View Article and Find Full Text PDF

Oxycodone for neuropathic pain and fibromyalgia in adults.

Cochrane Database Syst Rev

June 2014

Department of Clinical Geratology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Oxford, Oxfordshire, UK, OX3 9DU.

Background: This review is one of a series on drugs used to treat neuropathic pain and fibromyalgia. These conditions are estimated to affect 3 to 10% of adults, and are difficult to treat. Although they probably have different aetiologies, neuropathic pain and fibromyalgia can respond to the same therapies.

View Article and Find Full Text PDF

An 85-year-old lady presented with a left middle cerebral artery territory infarct. Several days into her admission she became hypoxic and haemodynamically unstable. A CT pulmonary angiogram showed bilateral pulmonary emboli, right-sided parenchymal cavitation due to infarction and an associated large pneumothorax.

View Article and Find Full Text PDF

Objectives: To examine predictors for 5-year survival in elderly stroke patients.

Materials And Methods: Prospective cohort study of 186 consecutive acute stroke patients aged ≥65 years admitted to Bankstown-Lidcombe Hospital, Australia 03/2002 to 03/2003. All subjects were followed up in 2007/8, at 5 years post-stroke, for outcome measures.

View Article and Find Full Text PDF

Background: Overt bleeding associated with low dose aspirin (LDA) is well-recognized, little attention is given to the possibility of association between LDA and occult bleeding, although this is known to occur in healthy volunteers. LDA is used increasingly in primary and secondary prevention of a number of medical conditions, many of which are common in older people, as is anemia. Anemia in older people is associated with adverse outcomes including disability, morbidity and mortality.

View Article and Find Full Text PDF

Background: delirium is under-diagnosed and under-treated in comparison to other common and serious acute disorders. The reasons for this are unclear.

Objective: we conducted a multicentre survey of knowledge of and attitudes to delirium in trainee general physicians.

View Article and Find Full Text PDF

Background: Oxycodone is a strong opioid agonist used to treat severe pain. It is commonly combined with milder analgesics such as paracetamol. This review updates a previous review that concluded, based on limited data, that all doses of oxycodone exceeding 5 mg, with or without paracetamol, provided analgesia in postoperative pain, but with increased incidence of adverse events compared with placebo.

View Article and Find Full Text PDF

Donepezil for mild cognitive impairment.

Cochrane Database Syst Rev

July 2006

University of Oxford, Department of Clinical Geratology, Radcliffe Infirmary, Woodstock Road, Oxford, UK OX2 6HE.

Background: Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or diagnostic criteria for MCI, and MCI remains a vague term and those so described are a heterogeneous population, consisting of people who may rapidly progress to dementia but also of people with stable cognitive deficits and some who may actually improve. Treatment in the very earliest stages of AD may delay progression to AD.

View Article and Find Full Text PDF

Cholinesterase inhibitors for Alzheimer's disease.

Cochrane Database Syst Rev

January 2006

University of Oxford, Department of Clinical Geratology, Radcliffe Infirmary, Woodstock Road, Oxford, UK, OX2 6HE.

Background: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease.

View Article and Find Full Text PDF

Donepezil for dementia due to Alzheimer's disease.

Cochrane Database Syst Rev

January 2006

University of Oxford, Department of Clinical Geratology, Radcliffe Infirmary, Woodstock Road, Oxford, UK, OX2 6HE.

Background: Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors.

View Article and Find Full Text PDF

Electrocardiographic (ECG) abnormalities have been observed in acute cerebrovascular events. This case-control study investigated the prevalence of ECG rhythms and ischemic changes in elderly stroke and medical patients. The ECG rhythms and ischemic changes of 97 elderly patients admitted with acute stroke or transient ischemic attack (TIA) were compared with those of 70 medical controls admitted during the same study period.

View Article and Find Full Text PDF

Velnacrine for Alzheimer's disease.

Cochrane Database Syst Rev

August 2004

Department of Clinical Geratology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford, UK, OX2 6HE.

Background: Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.

View Article and Find Full Text PDF

Donepezil for dementia due to Alzheimer's disease.

Cochrane Database Syst Rev

September 2003

Department of Clinical Geratology, University of Oxford, Oxford, UK, OX2 6HE.

Background: Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors.

View Article and Find Full Text PDF

Selegiline for Alzheimer's disease.

Cochrane Database Syst Rev

March 2003

Department of Clinical Geratology, University of Oxford, Oxford, UK, OX2 6HE.

Background: Alzheimer's disease is the most common cause of dementia in older people accounting for some 60% of cases with late-onset cognitive deterioration. It is now thought that several neurotransmitter dysfunctions are involved from an early stage in the pathogenesis of Alzheimer's disease-associated cognitive decline. The efficacy of selegiline for symptoms of Alzheimer's disease remains controversial and is reflected by its low rate of prescription and the lack of approval by several regulatory authorities in Europe and elsewhere.

View Article and Find Full Text PDF